Black Diamond Therapeutics, Inc. (BDTX)

BDTX Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	5.09	-69.68	-82.44	-91.17	-125.6	-67.25
Depreciation & Amortization	0.34	0.34	0.44	0.51	0.21	0.05
Loss (Gain) From Sale of Assets	-0.11	-0.09	0.36	-2.23	0	-
Loss (Gain) From Sale of Investments	-3.27	-3.78	-1.17	0.54	2.18	1.7
Loss (Gain) on Equity Investments	-	-	-	2.25	-	-
Stock-Based Compensation	10.61	10.63	9.6	12.2	14.04	7.77
Other Operating Activities	3.01	2.97	2.81	2.73	2.01	0.55
Change in Accounts Payable	1.43	1.68	0.6	-2.23	1.57	1.07
Change in Other Net Operating Assets	-4.82	-4.38	3.09	-7.67	5.45	3.97
Operating Cash Flow	12.31	-62.3	-66.72	-85.08	-100.15	-52.15
Capital Expenditures	-	-	-0.03	-0.19	-2.71	-0.14
Sale of Property, Plant & Equipment	0.11	0.09	0.1	0.01	-	-
Investment in Securities	39.14	16.87	16.28	53.55	133.32	-281.55
Investing Cash Flow	39.25	16.97	16.35	53.37	130.61	-281.69
Issuance of Common Stock	21.45	25.55	71.93	0.18	0.73	216.22
Other Financing Activities	-	-	-	-	-	-1.28
Financing Cash Flow	21.45	25.55	71.93	0.18	0.73	214.94
Net Cash Flow	73	-19.79	21.56	-31.54	31.19	-118.89
Free Cash Flow	12.31	-62.3	-66.75	-85.27	-102.86	-52.29
Free Cash Flow Per Share	0.22	-1.13	-1.52	-2.35	-2.84	-1.59
Levered Free Cash Flow	10.1	-35.76	-37.65	-55.39	-59.04	-30.94
Unlevered Free Cash Flow	10.1	-35.76	-37.65	-55.39	-59.04	-30.94
Change in Net Working Capital	0.2	-0.67	-6.38	9.88	-8.72	-4.87

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q